Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma

被引:5
作者
Horiuchi, Kiyomi [1 ]
Fujimoto, Mikiko [1 ]
Hidenori, Kamio [1 ]
Yoshida, Yusaku [1 ]
Noguchi, Eiichiro [2 ]
Omi, Yoko [1 ]
Okamoto, Takahiro [1 ]
机构
[1] Tokyo Womens Med Univ, Dept Endocrine Surg, 8-1 Kawada Cho Shinjuku Ku, Tokyo 1628666, Japan
[2] Tokyo Womens Med Univ, Dept Breast Surg, 8-1 Kawada Cho Shinjuku Ku, Tokyo 1628666, Japan
关键词
SUPPRESSION THERAPY; CANCER; SURVIVAL; LOBECTOMY; SURGERY; EXTENT; RECURRENCE; MANAGEMENT; ASSOCIATION; ABLATION;
D O I
10.1007/s00268-023-07073-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background The management of intermediate-risk group of papillary thyroid cancer (PTC) is still vague, particularly regarding whether or not total thyroidectomy, postoperative radioactive iodine ablation (RAI-a), and postoperative TSH suppression are mandatory. Methods This retrospective study evaluated 680 PTC patients from 2010 to 2017, who were classified into the three risk groups as low, intermediate, and high-risk groups according to the criteria of the Japanese Association of Endocrine Surgeons (JAES) 2010 and underwent surgery according to the JAES guidelines. We retrospectively collected patient data for analyses of disease-free survivals in the intermediate-risk group patients. Results We performed surgery on 680 PTC patients from 2010 to 2017. Of them, 297 were classified as the intermediate-risk group. DFS was not statistically significantly different in patients with/without total thyroidectomy and postoperative TSH suppression therapy. For RAI-a, DFS (95% confidence interval) at 3, 5, and 8 years were 93.2% (84.6 similar to 97.2), 81.6% (68,3 similar to 90.2), and 70.7% (51.4 similar to 84.6) in patients with postoperative RAI-a and 100%, 100%, and 100% in patients without postoperative RAI-a after total thyroidectomy, respectively. DFS of patients without RAI-a was superior to those with RAI-a (P < 0.0004). Multivariable analysis by stepwise selection method revealed that postoperative RAI-a was a risk factor with a hazard ratio of 5.69. (95% CI 1.998-16.21) (P = 0.001131). Conclusions Our study did not show the efficacy of RAI-a in patients with intermediate-risk PTC. This study implies that judging the efficacy of adjuvant therapy such as RAI or TSh suppression in intermediate-risk patients is difficult.
引用
收藏
页码:2464 / 2473
页数:10
相关论文
共 33 条
  • [21] Surgery for Papillary Thyroid Carcinoma Is Lobectomy Enough?
    Mendelsohn, Abie H.
    Elashoff, David A.
    Abemayor, Elliot
    St John, Maie A.
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2010, 136 (11) : 1055 - 1061
  • [22] Radioactive iodine treatment for differentiated thyroid carcinoma in Japan
    Okamoto, Takahiro
    [J]. SURGERY, 2010, 147 (03) : 432 - 433
  • [23] Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study
    Park, Suyeon
    Kim, Won Gu
    Han, Minkyu
    Jeon, Min Ji
    Kwon, Hyemi
    Kim, Mijin
    Sung, Tae-Yon
    Kim, Tae Yong
    Kim, Won Bae
    Hong, Suck Joon
    Shong, Young Kee
    [J]. THYROID, 2017, 27 (09) : 1164 - 1170
  • [24] Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers
    Rajjoub, Samer R.
    Yan, Huan
    Calcatera, Natalie A.
    Kuchta, Kristine
    Wang, Chi-Hsiung E.
    Lutfi, Waseem
    Moo-Young, Tricia A.
    Winchester, David J.
    Prinz, Richard A.
    [J]. SURGERY, 2018, 163 (05) : 1134 - 1143
  • [25] Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer
    Ruel, Ewa
    Thomas, Samantha
    Dinan, Michaela
    Perkins, Jennifer M.
    Roman, Sanziana A.
    Sosa, Julie Ann
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (04) : 1529 - 1536
  • [26] Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
    Schlumberger, Martin
    Catargi, Bogdan
    Borget, Isabelle
    Deandreis, Desiree
    Zerdoud, Slimane
    Bridji, Boumediene
    Bardet, Stephane
    Leenhardt, Laurence
    Bastie, Delphine
    Schvartz, Claire
    Vera, Pierre
    Morel, Olivier
    Benisvy, Danielle
    Bournaud, Claire
    Bonichon, Francoise
    Dejax, Catherine
    Toubert, Marie-Elisabeth
    Leboulleux, Sophie
    Ricard, Marcel
    Benhamou, Ellen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (18) : 1663 - 1673
  • [27] Does Postoperative Thyrotropin Suppression Therapy Truly Decrease Recurrence in Papillary Thyroid Carcinoma? A Randomized Controlled Trial
    Sugitani, Iwao
    Fujimoto, Yoshihide
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (10) : 4576 - 4583
  • [28] Management of low-risk papillary thyroid carcinoma: Unique conventional policy in Japan and our efforts to improve the level of evidence
    Sugitani, Iwao
    Fujimoto, Yoshihide
    [J]. SURGERY TODAY, 2010, 40 (03) : 199 - 215
  • [29] Therapeutic Strategy for Differentiated Thyroid Carcinoma in Japan Based on a Newly Established Guideline Managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons
    Takami, Hiroshi
    Ito, Yasuhiro
    Okamoto, Takahiro
    Yoshida, Akira
    [J]. WORLD JOURNAL OF SURGERY, 2011, 35 (01) : 111 - 121
  • [30] The Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery, 2018, JAES JSTS, V35